Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zogenix' ZX008 Emerges As Strong Contender In Rare Epilepsy

Executive Summary

Strong efficacy and a clean safety profile – with no cardiovascular signal – in another Phase III study bode well for filings of Zogenix's ZX008 in the fourth quarter.

Advertisement

Related Content

EU Accelerated Assessment Tracker: Second Half Trumps First By Far
Keeping Track: Novel Approvals For Diacomit, Takhzyro And Oxervate; CRLs For Mallinckrodt And Allergan
Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows
GW's Epidiolex Approval Encouraging For Pharma-grade Cannabinoid Pipeline
Gottlieb: Epidiolex Approval Covers One Specific Cannabidiol Medication, Not Marijuana
Stellar Zogenix Phase III Epilepsy Data Lift ZX008's Competitive Position
REDUX/PONDIMIN WITHDRAWALS PROVOKE QUESTIONS OF OFF-LABEL USE PROVISIONS IN FDA REFORM BILL; FEN-PHEN CITED IN KENNEDY ATTEMPT TO CHANGE DEVICE PROVISIONS

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel